Thomas Gajewski to Protein Kinase Inhibitors
This is a "connection" page, showing publications Thomas Gajewski has written about Protein Kinase Inhibitors.
Connection Strength
0.345
-
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
Score: 0.285
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
Score: 0.040
-
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
Score: 0.020